Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) hit a new 52-week low on Monday . The company traded as low as $17.64 and last traded at $17.87, with a volume of 16264 shares. The stock had previously closed at $19.01.
Analyst Ratings Changes
Several analysts recently weighed in on the company. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, December 20th. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $49.00 price target on the stock. Lifesci Capital began coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set an "outperform" rating and a $41.00 price target on the stock. Leerink Partnrs upgraded shares of Oruka Therapeutics to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, Wedbush restated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $43.17.
View Our Latest Report on Oruka Therapeutics
Oruka Therapeutics Trading Down 0.3 %
The stock has a 50-day moving average price of $23.50.
Institutional Trading of Oruka Therapeutics
Several large investors have recently made changes to their positions in ORKA. Franklin Resources Inc. bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth $17,661,000. Geode Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $343,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at approximately $11,699,000. Wellington Management Group LLP acquired a new position in Oruka Therapeutics during the 3rd quarter worth approximately $2,013,000. Finally, RTW Investments LP bought a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $45,359,000. Institutional investors and hedge funds own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
Further Reading
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
